The news hit the wire late last night: Cybin announced their conditional approval for listing on the NYSE American.
We’d been waiting for something like this, wondering which psychedelic player would be the next to make the big jump. In our coverage of which firm would be the next to go to the NASDAQ, we had Cybin at the top of the list. Well, we were close. Cybin was next but they’ve gone to the NYSE American instead.
From the press release:
“Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions,” said Doug Drysdale, Cybin’s CEO.
The listing approval is conditional, subject to the final approval of the NYSE American and the satisfaction of all regulatory requirements. Cybin will maintain its current listing on the NEO Exchange and has reserved the ticker CYBN on the NYSE American.
We reached out to Doug Drysdale, Cybin’s CEO, and he took a moment from what is surely a very busy day to tell us:
“The Cybin team continues to impress me with their relentless dedication to our mission. This milestone is another example of their commitment to progress our development programs, through providing expanded access to investors.”
We’ll continue to follow this story and work with the Cybin team to get more info. In the meantime, this is great news for Cybin and its investors. The firm continues to impress, with its recent planned expansion into the US market and receiving bullish price coverage from major analysts.
Note: The NYSE American is an exchange owned by the New York Stock Exchange. Formerly the AMEX exchange, it is one of the oldest and biggest exchanges in the US. The NYSE American focuses on small to medium market cap companies, giving firms the exposure and growth support of the NYSE family. See here for more information.